Loading stock data…
Traws Pharma, Inc. (TRAW)
$0.82-0.01 (-0.76%)
After Hours$0.84+0.02 (+2.35%)· Last close Jun 29
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Traws Pharma, Inc. in the Healthcare sector is trading at $0.82 with a market capitalization of $22M. Wall Street consensus targets $1.00 (1 analysts), implying a +21.8% move over the next 12 months. The stock is currently near its 52-week low of $0.64, remaining 55.4% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 22 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +21.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 22) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0↓ | $2.73M↑ | $57,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$6.95M↑ | -$7.37M↓ | -$4.05M↓ | -$1.25M↑ | -$5.20M |
| Net Income | -$7.11M↑ | -$7.44M↓ | -$3.96M↓ | -$915,000↓ | $21.49M |
Peer Comparison
JNJUNHPFE
Fundamentals
Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small-molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$21.97M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
365.79%
Volume
Today's trading volume
334,986
Recent News
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
SpaceX initiated, Salesforce upgraded: Wall Street's top analyst calls
Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study
Traws Pharma (NASDAQ:TRAW) shares fell sharply in premarket trading on Monday after the company revealed that UK regulators had delayed a planned mid-stage clinical trial for its influenza treatment candidate. The setback adds to previous regulatory challenges facing the programme and prompted investors to reassess the drug’s development timeline.
Why Did TRAW Stock Slump 28% After Hours?
Traws is delaying a planned human study of its lead flu treatment, tivoxavir marboxil, after feedback from a UK regulator.
Sector Update: Healthcare Stocks Lower Late Afternoon
Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index and the State Stree
Traws Pharma, Inc. (TRAW) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Traws Pharma, Inc. (TRAW) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.